AngioDynamics (NASDAQ:ANGO) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a research note published on Wednesday, Benzinga reports. They currently have a $14.00 price target on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ Q4 2024 earnings at ($0.21) EPS, Q2 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.68) EPS.

Separately, Oppenheimer upgraded AngioDynamics from a market perform rating to an outperform rating and set a $12.00 price objective for the company in a research report on Friday, April 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $13.25.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $6.17 on Wednesday. The stock has a market capitalization of $247.17 million, a price-to-earnings ratio of -1.27 and a beta of 0.67. AngioDynamics has a one year low of $5.26 and a one year high of $11.38. The company’s 50-day simple moving average is $6.07 and its 200-day simple moving average is $6.33.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, April 4th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). AngioDynamics had a negative return on equity of 3.48% and a negative net margin of 60.21%. As a group, research analysts forecast that AngioDynamics will post -0.57 EPS for the current year.

Insider Activity

In other AngioDynamics news, CEO James C. Clemmer bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average cost of $6.70 per share, with a total value of $67,000.00. Following the completion of the purchase, the chief executive officer now directly owns 539,066 shares in the company, valued at $3,611,742.20. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in AngioDynamics by 37.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,105 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 2,491 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of AngioDynamics by 11.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,010 shares of the medical instruments supplier’s stock valued at $249,000 after acquiring an additional 3,442 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in AngioDynamics by 85.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,054,022 shares of the medical instruments supplier’s stock worth $7,705,000 after purchasing an additional 486,501 shares during the period. Jump Financial LLC grew its position in AngioDynamics by 129.3% during the 3rd quarter. Jump Financial LLC now owns 118,080 shares of the medical instruments supplier’s stock worth $863,000 after purchasing an additional 66,590 shares in the last quarter. Finally, Barclays PLC raised its stake in AngioDynamics by 43.4% during the 3rd quarter. Barclays PLC now owns 38,155 shares of the medical instruments supplier’s stock valued at $280,000 after purchasing an additional 11,556 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.